Article
Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
Clinical lung cancer - 1 May 2022
Haratake Naoki, Hayashi Hidetoshi, Shimokawa Mototsugu, Nakano Yusuke, Azuma Koichi, Oki Masahide, Ota Keiichi, Yoshioka Hiroshige, Sakamoto Tomohiro, Yamamoto Nobuyuki, Nakagawa Kazuhiko, Seto Takashi
Abstract excerpt
INTRODUCTION: Osimertinib is a standard first-line treatment for non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor gene (EGFR). However, tumors with the L858R mutation appear to be less sensitive to EGFR-tyrosine kinase inhibitors (TKIs) than those with exon-19 deletions, and subgroup analysis of the FLAURA study revealed that osimertinib did not significantly prolong...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.